• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by IRIDEX Corporation

    4/8/25 4:31:19 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $IRIX alert in real time by email
    8-K
    IRIDEX CORP NASDAQ false 0001006045 0001006045 2025-04-07 2025-04-07

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

    April 7, 2025

    (Date of Report (date of earliest event reported))

     

     

    IRIDEX CORPORATION

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   0-27598   77-0210467
    (State or other jurisdiction of
    incorporation or organization)
     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification Number)

    1212 Terra Bella Avenue

    Mountain View, California 94043

    (Address of principal executive offices, including zip code)

    (650) 940-4700

    (Registrant’s telephone number, including area code)

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Class

     

    Trading

    Symbol

     

    Name of Exchange

    on Which Registered

    Common Stock, par value $0.01 per share   IRIX   Nasdaq Capital Market

     

     

     


    Item 5.02.

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.

    Resignation of Director

    On March 19, 2025, IRIDEX Corporation (the “Company”) entered into a Securities Purchase Agreement, Note Purchase Agreement and Investor Rights Agreement (the “Rights Agreement”, and together with the Securities Purchase Agreement and Note Purchase Agreement, the “Novel Transaction”) with Novel Inspiration International Co., Ltd. (“Novel”). Pursuant to the Rights Agreement, the Company agreed that the size of the Company’s Board of Directors (the “Board”) would be maintained at five directors.

    Kenneth E. Ludlum has agreed to resign and has submitted his resignation to the Company’s Board and all committees thereof, effective as of April 7, 2025. Mr. Ludlum is not resigning due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices but to fulfill the provisions of the Rights Agreement.

    The Board expresses its appreciation to Mr. Ludlum for his years of dedicated service to the Board and the committees on which he served.

    The Rights Agreement listed below as Exhibit 10.1 and is hereby incorporated herein by reference. The foregoing description of the Rights Agreement is only a summary, does not purport to be complete, and is qualified in its entirety by reference to Exhibit 10.1.

     

    Item 9.01.

    Financial Statements and Exhibits.

     

    (d)

    Exhibits

     

    Exhibit
    No.

      

    Description

    10.1    Investor Rights Agreement, dated March 19, 2025 by and between the Registrant and Novel Inspiration International Co., Ltd., (incorporated herein by reference to Exhibit 4.1 to the Current Report on Form 8-K filed on March 20, 2025).
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    -2-


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      IRIDEX CORPORATION

    By:

     

    /s/ Patrick Mercer

     

    Patrick Mercer

     

    President and Chief Executive Officer

    Date: April 8, 2025

     

    -3-

    Get the next $IRIX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IRIX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IRIX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Dizon Romeo R bought $1,451 worth of shares (1,305 units at $1.11), increasing direct ownership by 13% to 11,205 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      5/13/25 5:35:24 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Financial Officer Dizon Romeo R bought $116 worth of shares (100 units at $1.16), increasing direct ownership by 1% to 9,900 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      5/12/25 5:53:31 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Financial Officer Dizon Romeo R bought $115 worth of shares (100 units at $1.15), increasing direct ownership by 1% to 9,800 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      5/9/25 4:46:56 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Dizon Romeo R bought $1,451 worth of shares (1,305 units at $1.11), increasing direct ownership by 13% to 11,205 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      5/13/25 5:35:24 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Financial Officer Dizon Romeo R bought $116 worth of shares (100 units at $1.16), increasing direct ownership by 1% to 9,900 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      5/12/25 5:53:31 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Financial Officer Dizon Romeo R bought $115 worth of shares (100 units at $1.15), increasing direct ownership by 1% to 9,800 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      5/9/25 4:46:56 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Iridex Reports First Quarter 2025 Financial Results

      MOUNTAIN VIEW, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended March 29, 2025. First Quarter 2025 Financial Highlights Total revenue was $11.9 million, compared to $11.8 million in the first quarter of 2024Cyclo G6® product family revenue was $3.2 million, an increase of 8% year-over-year, compared to $3.0 million in the prior year quarter Sold 13,900 Cyclo G6 probes compared to 13,300 in the prior year quarterSold 24 Cyclo G

      5/13/25 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Iridex to Report First Quarter 2025 Financial Results on May 13, 2025

      MOUNTAIN VIEW, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company plans to release financial results for the first quarter 2025 and provide a business update after the close of trading on Tuesday, May 13, 2025. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-888-596-4144 and providing conference ID: 698002. A live and re

      4/30/25 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Iridex Announces Preliminary Operational and Financial Results for the First Quarter 2025

      MOUNTAIN VIEW, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the first quarter ended March 29, 2025. First Quarter 2025 Results Total revenue is expected to be between $11.8 million and $12.0 million, compared to $11.8 million in the comparable quarter of 2024Sold approximately 13,900 Cyclo G6 probes, compared to 13,300 in the prior year quarterSold approximately 24 Cyclo G6 Laser Systems, compared to 22 in the

      4/14/25 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Financials

    Live finance-specific insights

    See more

    $IRIX
    SEC Filings

    See more

    $IRIX
    Leadership Updates

    Live Leadership Updates

    See more
    • Iridex Reports First Quarter 2025 Financial Results

      MOUNTAIN VIEW, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended March 29, 2025. First Quarter 2025 Financial Highlights Total revenue was $11.9 million, compared to $11.8 million in the first quarter of 2024Cyclo G6® product family revenue was $3.2 million, an increase of 8% year-over-year, compared to $3.0 million in the prior year quarter Sold 13,900 Cyclo G6 probes compared to 13,300 in the prior year quarterSold 24 Cyclo G

      5/13/25 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Iridex to Report First Quarter 2025 Financial Results on May 13, 2025

      MOUNTAIN VIEW, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company plans to release financial results for the first quarter 2025 and provide a business update after the close of trading on Tuesday, May 13, 2025. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-888-596-4144 and providing conference ID: 698002. A live and re

      4/30/25 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Iridex to Host Strategic Vision Call on April 16, 2025

      MOUNTAIN VIEW, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will host a special call on April 16, 2025 to introduce Iridex and Novel's strategic vision for the Company following Novel's recent strategic investment in Iridex. The Company's management team will host a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing 888-596-4144 and providing conference ID: 9584140. A live an

      4/9/25 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 10-Q filed by IRIDEX Corporation

      10-Q - IRIDEX CORP (0001006045) (Filer)

      5/13/25 4:43:02 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • IRIDEX Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - IRIDEX CORP (0001006045) (Filer)

      5/13/25 4:16:38 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form DEFA14A filed by IRIDEX Corporation

      DEFA14A - IRIDEX CORP (0001006045) (Filer)

      4/28/25 4:13:02 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Iridex Appoints Patrick Mercer as Chief Executive Officer

      MOUNTAIN VIEW, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the appointment of Patrick Mercer as the Company's Chief Executive Officer and President effective October 1, 2024. Previously Mr. Mercer served as the Company's Chief Operating Officer and President. David Bruce, the Company's prior Chief Executive Officer, is transitioning from the Company. Coincident to Mr. Mercer's appointment, Scott Shuda was appointed Executive Chairman of the Company's board of directors. M

      10/3/24 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Iridex Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust

      MOUNTAIN VIEW, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation, headquartered in Mountain View, California, and Imperial College Healthcare NHS Trust in London, today announced the first patient enrollment in a collaborative medical research study and registry evaluating the treatment of glaucoma with MicroPulse® Transscleral Laser Therapy (TLT) using Iridex' Cyclo G6® Laser and the MicroPulse P3® Delivery Device. This partnership establishes a large-scale enrollment platform to advance clinical research. David I. Bruce, President and CEO of Iridex, shared: "The first patient enrollment in this partnership with Imperial College Healthcare NHS Trust is the first step toward mu

      1/24/24 8:00:00 AM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Iridex Announces the Appointment of Beverly Huss to its Board of Directors

      MOUNTAIN VIEW, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the appointment of Beverly Huss to its board of directors, effective, March 17, 2022. In connection with Ms. Huss' appointment to the board, the size of the board was increased from five to six members as of the Effective Date. "I am very pleased to welcome Beverly to our board of directors," said Scott Shuda, chairman of the board of Iridex. "Beverly's extensive management and board experience in the medical device industry and proven track record with non-invasive a

      3/21/22 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital reiterated coverage on Iridex with a new price target

      Roth Capital reiterated coverage of Iridex with a rating of Buy and set a new price target of $11.00 from $9.00 previously

      5/12/21 11:32:01 AM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Roth Capital reiterated coverage on IRIDEX with a new price target

      Roth Capital reiterated coverage of IRIDEX with a rating of Buy and set a new price target of $9.00 from $6.00 previously

      3/9/21 8:09:06 AM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Roth Capital reiterated coverage on Iridex with a new price target

      Roth Capital reiterated coverage of Iridex with a rating of Buy and set a new price target of $9.00 from $6.00 previously

      3/3/21 12:29:03 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by IRIDEX Corporation

      SC 13D - IRIDEX CORP (0001006045) (Subject)

      11/23/22 4:57:01 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13D filed by IRIDEX Corporation

      SC 13D - IRIDEX CORP (0001006045) (Subject)

      9/20/22 2:06:59 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by IRIDEX Corporation (Amendment)

      SC 13G/A - IRIDEX CORP (0001006045) (Subject)

      2/10/22 8:17:17 AM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care